Finch Therapeutics is a biotechnology company founded in 2017, specializing in microbiome assets. Its flagship product, CP101, displayed promising clinical trial results in treating recurrent C. difficile infection. The company also holds pre-clinical assets targeting ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Finch boasts a robust intellectual property estate, with over 70 patents in the microbiome therapeutics field. However, in January 2023, the company made the strategic decision to discontinue the Phase 3 trial of CP101 and shift focus towards realizing the value of its intellectual property estate and other assets.
Finch Therapeutics operates in the biotechnology, health and wellness, and machine learning industries. In 2020, the company secured a significant $90.00M Series D investment from a consortium of notable investors including Avemir Growth Capital, MSD Capital, MSD Partners, OMX Ventures, Humboldt Fund, Symbiosis Group, Octave Group, Willett Advisors LLC, Susquehanna International Group (SIG), Octave Ventures LLC.
